Fáddáevttohusat
Fáddáevttohusat
- Vaccination
- COVID-19 44
- COVID-19 (Disease) 44
- SARS-CoV-2 44
- COVID-19 Vaccines 40
- Vaccines 40
- prevention & control 35
- Development 33
- Coronavirus infections 28
- immunology 28
- Research 26
- Betacoronavirus 22
- Coronavirus Infections 20
- Drug Development 18
- drug therapy 17
- virology 17
- Coronaviruses 16
- drug effects 16
- Immunological aspects 12
- Viral Vaccines 12
- COVID-19 Pandemic, 2020- 10
- Mutation 10
- genetics 10
- Pandemics 9
- Clinical Trials as Topic 8
- Clinical trials 8
- Immunity 8
- Spike Glycoprotein, Coronavirus 8
- Treatment 8
- Viral vaccines 8
-
1
Opposition to vaccination a transatlantic discussion /
Almmustuhtton 2018Viečča ollesdeavstta
Elektrovnnalaš Jietna -
2
Prescribing medications to children a GP's view /
Almmustuhtton 2018Viečča ollesdeavstta
Elektrovnnalaš Jietna -
3
Towards developing a universal influenza vaccine
Almmustuhtton 2018Viečča ollesdeavstta
Elektrovnnalaš Jietna -
4
Monkeypox etiopathogenesis, prevention, and treatments /
Almmustuhtton 2022Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
5
Comparison of immune resilience induced by vaccination versus COVID recovery
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
6
mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
7
SARS-CoV-2 variants implications for immunity and vaccine development /
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
8
Emergence of blood clotting disorders resulting from COVID vaccines inoculations
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
9
SARS-CoV-2 evolution within and between individuals
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
10
The immune system response to the SARS-CoV-2 virus March 2021 update /
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
11
SARS-CoV-2 vaccine rollout campaigns
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
12
SARS-CoV-2 mutations phenotypes and implications for vaccine development /
Almmustuhtton 2021Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
13
The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
14
Imperial College London's saRNA Vaccine - COVAC1
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
15
Human challenge trials for vaccines against COVID-19
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
16
The development of SARS-CoV-2 vaccines
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
17
Nanotechnologies in the fight against coronaviruses
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
18
Development of an intranasal vaccine for SARS-CoV-2
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
19
COVID-19 epidemiology and potential treatments follow up interview /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna -
20
Elite controllers of HIV from discovery to future therapies /
Almmustuhtton 2020Viečča ollesdeavstta
Series
Elektrovnnalaš Jietna